Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 1:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 16,119 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Skin Disorder Clear all
Not listed Not applicable Interventional Accepts healthy volunteers

The Effects of Almond on Facial Skin Collagen and Wrinkles

NCT06074276
View directory record Official record
Conditions
Collagen Degeneration, Wrinkle, Pigmentation, Elastic Skin
Interventions
Food: whole almonds, Food: non-nut snack
Other
Lead sponsor
Integrative Skin Science and Research
Industry
Eligibility
35 Years to 70 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 18, 2024 · Synced Oct 28, 2026, 1:03 PM EDT
Not listed Not applicable Interventional

Clinical Study Of Affinity Versus SOC In The Management Of VLUs

NCT04901013
View directory record Official record
Conditions
Venous Leg Ulcer
Interventions
Affinity
Other
Lead sponsor
Organogenesis
Industry
Eligibility
18 Years to 85 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Carlsbad, California
Source: ClinicalTrials.gov public record
Updated Sep 8, 2021 · Synced Oct 28, 2026, 1:03 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Bermekimab in Patients With Moderate to Severe Atopic Dermatitis

NCT04021862
View directory record Official record
Conditions
Atopic Dermatitis, Eczema
Interventions
Bermekimab Monoclonal Antibody, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
17
States / cities
Huntington Beach, California • Coral Gables, Florida • Doral, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 28, 2026, 1:03 PM EDT
Completed Phase 1 Interventional Results available

Safety, Tolerability, and Pharmacokinetic (PK) Study of DHES0815A in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Breast Cancer

NCT03451162
View directory record Official record
Conditions
Breast Cancer
Interventions
DHES0815A
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
4
States / cities
New Haven, Connecticut • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Oct 28, 2026, 1:03 PM EDT
Completed Phase 2 Interventional Results available

Open Label Photo-Documentation Study Of BPX-01 Minocycline Gel

NCT02946788
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Minocycline
Drug
Lead sponsor
BioPharmX, Inc.
Industry
Eligibility
18 Years to 40 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Coral Gables, Florida • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Oct 28, 2026, 1:03 PM EDT
Completed No phase listed Observational

Registry of Mastectomy for Breast Cancer Risk Reduction

NCT00555503
View directory record Official record
Conditions
Quality of Life, Mastectomy, Breast Neoplasms, Genetic Predisposition to Disease, Adjustment Disorder
Interventions
Not listed
Lead sponsor
Georgetown University
Other
Eligibility
18 Years to 70 Years
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Dec 2, 2016 · Synced Oct 28, 2026, 1:03 PM EDT
Completed Early Phase 1 Interventional

Phase 1 Study of ULSC in Patients With Polymyositis (PM) and Dermatomyositis (DM)

NCT04723303
View directory record Official record
Conditions
Polymyositis, Dermatomyositis
Interventions
Umbilical Cord Lining Stem Cells
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 24, 2025 · Synced Oct 28, 2026, 1:03 PM EDT
Recruiting No phase listed Observational

Study of Chediak-Higashi Syndrome

NCT00005917
View directory record Official record
Conditions
Chediak-Higashi Syndrome
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
1 Month to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 28, 2026, 1:03 PM EDT
Terminated Phase 2 Interventional Results available

Docetaxel Chemotherapy and Pembrolizumab Plus Interleukin-12 Gene Therapy in Triple Negative Breast Cancer

NCT04095689
View directory record Official record
Conditions
Triple Negative Breast Cancer, Anthracycline-refractory TNBC
Interventions
Docetaxel, Pembrolizumab, IL-12 gene therapy
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 28, 2026, 1:03 PM EDT
Completed Not applicable Interventional

Exercise in Improving Mobility and Reducing Fatigue and/or Weakness in Older Cancer Survivors

NCT00335491
View directory record Official record
Conditions
Bladder Cancer, Breast Cancer, Colorectal Cancer, Esophageal Cancer, Fatigue, Lung Cancer, Lymphoma, Ovarian Cancer, Prostate Cancer
Interventions
exercise intervention, complementary or alternative medicine procedure, fatigue assessment and management, physical therapy
Behavioral · Procedure
Lead sponsor
University of Utah
Other
Eligibility
60 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 30, 2011 · Synced Oct 28, 2026, 1:03 PM EDT
Completed Phase 2 Interventional Results available

Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer

NCT00479674
View directory record Official record
Conditions
Breast Cancer
Interventions
Abraxane, Bevacizumab, Carboplatin
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
4
States / cities
Charlotte, North Carolina • Concord, North Carolina • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2015 · Synced Oct 28, 2026, 1:03 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis

NCT07230860
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
JNJ-95597528, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
12
States / cities
Fountain Valley, California • Los Angeles, California • Santa Ana, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 28, 2026, 1:03 PM EDT
Not listed Not applicable Interventional

Dermacell ADM Without Basement Membrane

NCT03667560
View directory record Official record
Conditions
Breast Cancer
Interventions
Dermacell ADM without basement membrane, FlexHD
Procedure
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 12, 2018 · Synced Oct 28, 2026, 1:03 PM EDT
Withdrawn No phase listed Observational

S0307A, Long-Term Bone Quality in Women With Breast Cancer Enrolled on Clinical Trial SWOG-S0307

NCT00873808
View directory record Official record
Conditions
Breast Cancer
Interventions
clodronate disodium, demeclocycline hydrochloride, ibandronate sodium, tetracycline hydrochloride, zoledronic acid, laboratory biomarker analysis, adjuvant therapy, computed tomography, dual x-ray absorptiometry
Drug · Other · Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 10, 2013 · Synced Oct 28, 2026, 1:03 PM EDT
Completed Phase 2 Interventional

An Efficacy and Safety Study of CNTO 136 in Patients With Active Lupus Nephritis

NCT01273389
View directory record Official record
Conditions
Lupus Nephritis
Interventions
CNTO 136, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
8
States / cities
Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2016 · Synced Oct 28, 2026, 1:03 PM EDT
Completed Phase 2 Interventional Results available

A Multi-Histology Phase II Study of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine (FdCyd + THU)

NCT00978250
View directory record Official record
Conditions
Head and Neck Neoplasms, Lung Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms
Interventions
5-Fluoro-2'-Deoxycytidine (FdCyd) + Tetrahydrouridine (THU)
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
4
States / cities
Davis, California • Duarte, California • South Pasadena, California + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2019 · Synced Oct 28, 2026, 1:03 PM EDT
Completed Phase 2 Interventional

Safety, Tolerability and Efficacy of BFH772 in Rosacea Patients

NCT01449591
View directory record Official record
Conditions
Erythemato-telangiectatic Rosacea
Interventions
BFH772 1% ointment, Vehicle ointment, Noritate® 1% cream
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
6
States / cities
Hot Springs, Arkansas • Ann Arbor, Michigan • Paramus, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 28, 2026, 1:03 PM EDT
Terminated Phase 1 Interventional Results available

PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors

NCT03685591
View directory record Official record
Conditions
Breast Neoplasms, Prostate Neoplasms, Neoplasms, Squamous Cell, Melanoma, Mesothelioma, Pancreatic Neoplasms, Colorectal Neoplasms, Carcinoma, Renal Cell, Liver Neoplasms
Interventions
PF-06952229, Enzalutamide
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
15
States / cities
Scottsdale, Arizona • Santa Monica, California • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Oct 28, 2026, 1:03 PM EDT
Recruiting No phase listed Observational

Deciphering the Genetic Architecture of Autoimmune Diseases

NCT06948110
View directory record Official record
Conditions
Autoimmune Diseases
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
18 Years to 115 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Oct 28, 2026, 1:03 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Proof of Concept Study of MTC896 Gel to Reduce Sebum Production on the Forehead of Healthy Male Volunteers

NCT01254162
View directory record Official record
Conditions
Oily Skin, Seborrhea
Interventions
MTC896 Gel
Drug
Lead sponsor
Mimetica Pty Limited
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
135 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Paramus, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 12, 2014 · Synced Oct 28, 2026, 1:03 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of ARQ-154 Foam in Subjects With Seborrheic Dermatitis

NCT04091646
View directory record Official record
Conditions
Seborrheic Dermatitis
Interventions
Roflumilast Foam 0.3%, Vehicle foam
Drug
Lead sponsor
Arcutis Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
22
States / cities
Fremont, California • Santa Monica, California • Coral Gables, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 28, 2026, 1:03 PM EDT
Completed Phase 3 Interventional

Combination Chemotherapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Has Spread to the Lymph Nodes

NCT00004125
View directory record Official record
Conditions
Breast Cancer
Interventions
cyclophosphamide, docetaxel, doxorubicin hydrochloride, paclitaxel, tamoxifen citrate, radiation therapy
Drug · Radiation
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2016
U.S. locations
48
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 28, 2026, 1:03 PM EDT
Withdrawn No phase listed Observational

Protocol for Postmenopausal Women at Increased Risk of Developing Breast Cancer

NCT00329017
View directory record Official record
Conditions
Breast Cancer
Interventions
Fine needle aspiration
Procedure
Lead sponsor
Carol Fabian, MD
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 10, 2019 · Synced Oct 28, 2026, 1:03 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Soy Isoflavones and Breast Cancer Risk Reduction

NCT00204490
View directory record Official record
Conditions
Breast Cancer
Interventions
isoflavones, carbohydrate
Dietary Supplement
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
30 Years to 42 Years · Female only
Enrollment
197 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2023
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 28, 2026, 1:03 PM EDT